Genfit S.A. (NASDAQ:GNFT) Sees Large Increase in Short Interest

Genfit S.A. (NASDAQ:GNFT) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 63,400 shares, an increase of 6.0% from the December 31st total of 59,800 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 10,100 shares, the short-interest ratio is currently 6.3 days.

Genfit Stock Performance

Shares of GNFT opened at $3.73 on Monday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.74 and a current ratio of 3.74. Genfit has a 12 month low of $3.35 and a 12 month high of $6.42. The firm has a fifty day simple moving average of $3.79 and a 200 day simple moving average of $4.45.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Genfit in a research note on Friday, October 11th.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.